Mazzi Mariana Torres, Hajdu Karina Lôbo, Ribeiro Priscila Rafaela, Bonamino Martín Hernán
Immunology and Tumor Biology Program - Research Coordination, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil.
Vice - Presidency of Research and Biological Collections (VPPCB), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
Immunother Adv. 2020 Nov 25;1(1):ltaa006. doi: 10.1093/immadv/ltaa006. eCollection 2021 Jan.
Chimeric antigen receptor (CAR)-T cell therapy represents a breakthrough in the immunotherapy field and has achieved great success following its approval in 2017 for the treatment of B cell malignancies. While CAR-T cells are mostly applied as anti-tumor therapy in the present, their initial concept was aimed at a more general purpose of targeting membrane antigens, thus translating in many potential applications. Since then, several studies have assessed the use of CAR-T cells toward non-malignant pathologies such as autoimmune diseases, infectious diseases and, more recently, cardiac fibrosis, and cellular senescence. In this review, we present the main findings and implications of CAR-based therapies for non-malignant conditions.
嵌合抗原受体（CAR）-T细胞疗法是免疫治疗领域的一项突破，自2017年被批准用于治疗B细胞恶性肿瘤后取得了巨大成功。虽然目前CAR-T细胞主要用作抗肿瘤疗法，但其最初的概念旨在更广泛地靶向膜抗原，从而衍生出许多潜在应用。从那时起，多项研究评估了CAR-T细胞在非恶性疾病中的应用，如自身免疫性疾病、传染病，以及最近的心脏纤维化和细胞衰老。在本综述中，我们介绍了基于CAR的疗法在非恶性疾病中的主要研究结果和意义。
